Factor Viii Or Derivative Affecting Or Utilizing Patents (Class 514/14.1)
-
Publication number: 20140274902Abstract: Provided are liquid and lyophilized rFVIII formulations, including full-length rFVIII (FL-rFVIII) formulations, B-domain deleted rFVIII (BDD-rFVIII) formulations, and BDD-rFVIII mutant (BDD-rVIII mutant) formulations. Also provided are liquid and lyophilized PEGylated rFVIII (PEG-rFVIII) formulations, including PEGylated full-length rFVIII (PEG-FL-rFVIII) formulations, PEGylated B-domain deleted rFVIII (PEG-BDD-rFVIII) formulations, and PEGylated BDD-rFVIII mutant (PEG-BDD-rFVIII mutant) formulations.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: BAYER HEALTHCARE, LLCInventors: Deqian Wang, Xinghang Ma, Nelly Tsvetkova
-
Publication number: 20140274903Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.Type: ApplicationFiled: April 29, 2014Publication date: September 18, 2014Applicant: NOVO NORDISK HEALTHCARE AGInventors: Carsten Behrens, Patrick W. Garibay, Magali Zundel, Niels Kristian Klausen, Soeren Bjoern
-
Patent number: 8835388Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.Type: GrantFiled: December 21, 2012Date of Patent: September 16, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Peter Turecek, Jueren Siekmann
-
Publication number: 20140249086Abstract: The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.Type: ApplicationFiled: October 18, 2012Publication date: September 4, 2014Applicant: CSL LimitedInventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
-
Patent number: 8822638Abstract: A peptide or peptide derivative comprising: (i)?WDLYFEIVW; (SEQ?ID?NO:?1) or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: GrantFiled: September 21, 2011Date of Patent: September 2, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Michael Dockal
-
Patent number: 8816054Abstract: Factor VIII variants and methods of use thereof are disclosed.Type: GrantFiled: April 2, 2012Date of Patent: August 26, 2014Assignee: The Children's Hospital of PhiladelphiaInventors: Valder Arruda, Rodney M. Camire, Nicholas Iacobelli
-
Patent number: 8802620Abstract: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.Type: GrantFiled: April 21, 2008Date of Patent: August 12, 2014Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), LFB BiotechnologiesInventors: Abdessatar Sami Chtourou, Sébastien Lacroix-Desmazes, Srinivas Kaveri, Suryasarathi Dasgupta, Jagaadeesh Bayry
-
Publication number: 20140221290Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.Type: ApplicationFiled: April 4, 2014Publication date: August 7, 2014Applicant: OCTAPHARMA AGInventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irene Agerkvist
-
Patent number: 8784816Abstract: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.Type: GrantFiled: October 23, 2012Date of Patent: July 22, 2014Assignee: Life Sciences Research Partners VZWInventors: Marc G. Jacquemin, Jean-Marie R. Saint-Remy
-
Publication number: 20140199262Abstract: The present invention provides a method for manufacturing a virus-free protein drug, comprising (a) a filtration step of filtering a virus-containing protein solution through a small-pore size virus removal membrane to obtain a virus-free protein solution, the filtration step (a) comprising (q) a low-pressure filtration step of filtering the solution through the small-pore size virus removal membrane at a filtration pressure of 0.30 kgf/cm2 or lower to obtain the virus-free protein solution, wherein the solution prior to filtration in the low-pressure filtration step (q) has a pH (X) and a salt ionic strength (Y (mM)) that satisfy the following equations 1 and 5: 0?Y?150X?590 (Equation 1) and 3.5?X?8.0 (Equation 5) or the following equations 4 and 5: Y=0 (Equation 4) and 3.5?X?8.0 (Equation 5).Type: ApplicationFiled: June 22, 2012Publication date: July 17, 2014Applicant: ASAHI KASEI MEDICAL CO., LTD.Inventors: Tomoko Hongo, Hirohisa Hayashida
-
Patent number: 8759293Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.Type: GrantFiled: November 12, 2010Date of Patent: June 24, 2014Assignee: Grifols Therapeutics Inc.Inventor: Thomas Barnett
-
Patent number: 8754194Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.Type: GrantFiled: December 21, 2007Date of Patent: June 17, 2014Assignee: CSL Behring GmbHInventors: Stefan Schulte, Thomas Weimer, Hubert Metzner
-
Publication number: 20140140987Abstract: A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin. The method further comprises administering an effective amount of a protein containing ApoA1/2/4, or administering an effective amount of a protein containing Factor II, Factor VII, Factor IX and Factor X in prothrombin complex concentrate. The method can further comprise administering an effective amount of fibrinogen, Factor VIII, high concentrate fibrinogen, thrombin. hepatitis B immune globulin (HBIG), anti-thrombin III (AT-III), protein C, fibronectin, protein S and protein M.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Publication number: 20140141065Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.Type: ApplicationFiled: November 19, 2013Publication date: May 22, 2014Inventors: R. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
-
Publication number: 20140134151Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: April 30, 2013Publication date: May 15, 2014Applicant: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, Uma Sinha
-
Publication number: 20140128325Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Applicant: CSL BEHRING GMBHInventors: Gerhard DICKNEITE, Ingo PRAGST, Henrique LESSA, Thorsten HAAS, Stefan ZEITLER
-
Patent number: 8703705Abstract: The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognized by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.Type: GrantFiled: May 17, 2010Date of Patent: April 22, 2014Assignee: Apitope International NVInventor: David Wraith
-
Patent number: 8697844Abstract: The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: GrantFiled: November 24, 2010Date of Patent: April 15, 2014Assignee: Novo Nordisk A/SInventors: Matthias Karl Dietrich Wiendahl, Lars Sejersgaard, Are Bogsnes
-
Patent number: 8691211Abstract: This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against Factor VIII, and compositions and methods that advantageously render subjects amenable to standard treatments for hemophilia A, including Factor VIII replacement therapy.Type: GrantFiled: March 10, 2010Date of Patent: April 8, 2014Assignee: Puget Sound Blood CenterInventor: Neil Cary Josephson
-
Publication number: 20140072561Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: ApplicationFiled: September 17, 2013Publication date: March 13, 2014Applicant: CSL BEHRING GMBHInventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Publication number: 20140057848Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.Type: ApplicationFiled: September 14, 2011Publication date: February 27, 2014Applicant: NOVO NORDISK A/SInventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
-
Patent number: 8637448Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: GrantFiled: September 13, 2011Date of Patent: January 28, 2014Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20140018297Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.Type: ApplicationFiled: June 12, 2013Publication date: January 16, 2014Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
-
Patent number: 8623824Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.Type: GrantFiled: February 22, 2008Date of Patent: January 7, 2014Assignees: Biomethodes, Hospices Civils de LyonInventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
-
Patent number: 8603979Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.Type: GrantFiled: July 10, 2009Date of Patent: December 10, 2013Assignee: CSL Behring GmbHInventors: Gerhard Dickneite, Ingo Pragst, Henrique Lessa, Thorsten Haas, Stefan Zeitler
-
Patent number: 8586538Abstract: The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.Type: GrantFiled: April 28, 2003Date of Patent: November 19, 2013Assignee: Stichting Sanquin BloedvoorzieningInventors: Koenraad Mertens, Arend N. Bovenschen, Jan Voorberg, Manfred Rieger, Friedrich Scheiflinger
-
Publication number: 20130296244Abstract: The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.Type: ApplicationFiled: November 4, 2011Publication date: November 7, 2013Applicants: Baxter Heathcare SA, Baxter International Inc.Inventors: Chee K. Lai, Roddy Kevin Stafford
-
Publication number: 20130296243Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.Type: ApplicationFiled: April 11, 2013Publication date: November 7, 2013Inventors: Hans-Peter Schwarz, Peter Turecek
-
Patent number: 8575102Abstract: The present invention provides conjugates encompassed by the following structure, wherein: D is a residue of an active agent bearing at least one amino group; and PEG-m is a methoxy end-capped poly(ethylene glycol), and further wherein the active agent is a coagulation factor having a molecular weight of greater than 100 kDa. Methods of making conjugates, and methods for administering conjugates, are also provided.Type: GrantFiled: July 31, 2009Date of Patent: November 5, 2013Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Samuel P. McManus, Mary J. Bossard
-
Patent number: 8575104Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: GrantFiled: June 24, 2009Date of Patent: November 5, 2013Assignee: CSL Behring GmbHInventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Patent number: 8563688Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: GrantFiled: April 16, 2009Date of Patent: October 22, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Michael Dockal
-
Publication number: 20130274194Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.Type: ApplicationFiled: March 11, 2013Publication date: October 17, 2013Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
-
Publication number: 20130267468Abstract: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.Type: ApplicationFiled: June 14, 2013Publication date: October 10, 2013Inventors: Myung-Sam CHO, Sham-Yuen Chan
-
Patent number: 8546332Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.Type: GrantFiled: February 19, 2009Date of Patent: October 1, 2013Assignee: Stichting Sanquin BloedvoorzieningInventors: Petrus Johannes Lenting, Jan Aart Van Mourik, Koenraad Mertens, Hans Pannekoek, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger
-
Patent number: 8536125Abstract: The invention relates to a method for stabilizing a bulk solution of recombinant protein for frozen storage, which comprises providing a partially-purified solution of recombinant protein which has a monovalent salt concentration of at least 100 mM, and adding a carbohydrate to said solution in an amount sufficient that, upon freezing, the solution has a glass transition temperature of ?56° C. or higher.Type: GrantFiled: April 30, 2012Date of Patent: September 17, 2013Assignee: Bayer Healthcare LLCInventors: Nelly Tsvetkova, Omkar Joshi, Paul Wu, Deqian Wang, Arnaud Desponds
-
Patent number: 8536126Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: GrantFiled: February 5, 2013Date of Patent: September 17, 2013Assignee: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Patent number: 8535892Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.Type: GrantFiled: September 23, 2011Date of Patent: September 17, 2013Assignee: Dyax Corp.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Publication number: 20130209444Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.Type: ApplicationFiled: January 30, 2013Publication date: August 15, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Patent number: 8501694Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: January 23, 2012Date of Patent: August 6, 2013Assignees: Emory University, Baxter International Inc., Baxter Healthcare SAInventors: John S. Lollar, Garrett E. Bergman
-
Publication number: 20130190242Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
-
Publication number: 20130184216Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: ApplicationFiled: February 6, 2013Publication date: July 18, 2013Applicants: University of Connecticut, Baxter International Inc.Inventors: Baxter International Inc., University of Connecticut
-
Patent number: 8476249Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.Type: GrantFiled: May 6, 2010Date of Patent: July 2, 2013Assignee: GlaxoSmithKline LLCInventors: Connie L. Erickson-Miller, Michael Arning
-
Patent number: 8466108Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.Type: GrantFiled: December 21, 2009Date of Patent: June 18, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
-
Publication number: 20130150302Abstract: The present invention provides a biocompatible polymer conjugated to FVIII via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIII, and pharmaceutical compositions comprising such conjugated forms of FVIII.Type: ApplicationFiled: April 28, 2011Publication date: June 13, 2013Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITEDInventor: William Henry
-
Publication number: 20130143818Abstract: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.Type: ApplicationFiled: May 29, 2012Publication date: June 6, 2013Applicant: Bayer HealthCare LLCInventors: Myung-Sam Cho, Sham-Yuen Chan
-
Patent number: 8454957Abstract: The invention is directed to methods for treating coagulation disorders, in particular, hemophilia. Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities.Type: GrantFiled: June 17, 2011Date of Patent: June 4, 2013Assignee: Stemnion, Inc.Inventors: David L. Steed, William J. Golden
-
Publication number: 20130137638Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: February 5, 2013Publication date: May 30, 2013Applicant: NOVO NORDISK A/SInventor: NOVO NORDISK A/S
-
Patent number: 8445448Abstract: The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.Type: GrantFiled: December 3, 2008Date of Patent: May 21, 2013Assignee: Apitope International NVInventor: David Wraith
-
Publication number: 20130123181Abstract: Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII.Type: ApplicationFiled: November 15, 2010Publication date: May 16, 2013Inventors: Kathleen Pratt, Ruth Ettinger, Eddie Arthur James
-
Publication number: 20130116182Abstract: Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII.Type: ApplicationFiled: November 15, 2010Publication date: May 9, 2013Inventors: Kathleen Pratt, Ruth Ettinger, Eddie Arthur James